Patents by Inventor Nan-Horng Lin
Nan-Horng Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11945785Abstract: Disclosed herein are heterocyclic compounds, for example, according to the following formula and analogs thereof: that inhibit the activity of FLT3. Also described are specific covalent inhibitors of FLT3. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the FLT3 inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of proliferative diseases or conditions, including hematological malignancies and other diseases or conditions dependent on FLT3 activity.Type: GrantFiled: December 29, 2022Date of Patent: April 2, 2024Assignee: Biomea Fusion, Inc.Inventors: David Sperandio, Xiaodong Wang, Thorsten A. Kirschberg, James T. Palmer, Thomas Butler, Solomon B. Ungashe, Neil Howard Squires, Nan-Horng Lin, Ravindra B. Upasani, Amna Trinity-Turjuman Adam, Yongli Su, Thu Phan
-
Publication number: 20230339867Abstract: Disclosed herein are heterocyclic compounds that inhibit the activity of FLT3. Also described are specific covalent inhibitors of FLT3. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the FLT3 inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of proliferative diseases or conditions, including hematological malignancies and other diseases or conditions dependent on FLT3 activity.Type: ApplicationFiled: December 29, 2022Publication date: October 26, 2023Inventors: David Sperandio, Xiaodong Wang, Thorsten A. Kirschberg, James T. Palmer, Thomas Butler, Solomon B. Ungashe, Neil Howard Squires, Nan-Horng Lin, Ravindra B. Upasani, Amna Trinity-Turjuman Adam, Yongli Su, Thu Phan
-
Patent number: 11628225Abstract: An antibody-drug conjugate (ADC) has a structure represented by Formula (I): a pharmaceutically acceptable salt thereof wherein Ab is an antibody without glycans (i.e., the protein portion an antibody); G1 and G2 are glycan moieties, which may be the same or different; Cn1 and Cn2 are conjugation moieties, which may be the same or different; L1 and L2 are linker moieties, which may be the same or different; D1 and D2; are drug units which may be the same or different; and x and y are independently an integer from 0 to 8, provided that x+y?0.Type: GrantFiled: November 14, 2017Date of Patent: April 18, 2023Assignee: CHO PHARMA INC.Inventors: Nan-Horng Lin, Charng-Sheng Tsai, Ting-Chun Hung, Hong-Yang Chuang
-
Publication number: 20230086137Abstract: Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the compound, as well as methods of using the compound, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.Type: ApplicationFiled: August 10, 2022Publication date: March 23, 2023Inventors: Priaynka SOMANATH, Daniel LU, Taisei KINOSHITA, Brian LAW, Thomas BUTLER, James T. PALMER, Nan-Horng LIN, Heow Meng TAN, Angelina Sau Man WONG, Siyi JAING, Hongyan HE
-
Patent number: 11135306Abstract: An antibody-drug conjugate (ADC) has a structure represented by Formula (I): [D2-L2-Cn2yG2-Ab-Sg1G1-L1-D1]x?? Formula (I) or a pharmaceutically acceptable salt thereof, wherein Ab is an antibody without glycans (i.e., the protein portion of an antibody); G1 and G2 are glycan moieties, which may be the same or different; Cn1 and Cn2 are conjugation moieties, which may be the same or different; L1 and L2 are linker moieties, which may be the same or different; D1 and D2 are drug units which may be the same or different; and x and y are independently an integer from 0 to 8, provided that x+y?0.Type: GrantFiled: November 14, 2017Date of Patent: October 5, 2021Assignee: CHO PHARMA INC.Inventors: Nan-Horng Lin, Charng-Sheng Tsai, Ting-Chun Hung, Hong-Yang Chuang
-
Patent number: 10745360Abstract: A compound for treating a protein kinase-related disease or disorder having a structure of formula (I) wherein L is NR8 or O; R1, R2, R3, R4, R5, R6 and R7 are defined herein. Compounds of formula (I) are useful for inhibition of protein kinases. Methods of using compounds of formula (I), stereoisomers, tautomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.Type: GrantFiled: June 15, 2015Date of Patent: August 18, 2020Assignee: Development Center for BiotechnologyInventors: Nan-Horng Lin, Chu-Bin Liao, Shao-Zheng Peng, Shih-Chieh Yen, Mann-Yan Kuo
-
Publication number: 20200115465Abstract: The present disclosure relates to anti-SSEA4 antibodies and bindings fragments thereof comprising specific complementarity determining regions capable of high affinity binding to SSEA4 molecules and SSEA4-associated expressing tumor cells, such as breast cancer, pancreatic cancer, and renal cancer cells. The anti-SSEA4 antibodies and binding fragments induce ADCC or CDC effects in the targeted tumor cells and inhibit and/or reduce the cancer/tumor proliferation. The present disclosure also provides anti-SSEA4 antibodies and binding fragments thereof as a pharmaceutical composition for treating cancer. In addition, the anti-SSEA4 antibodies and binding fragments are useful in the diagnosis of cancers.Type: ApplicationFiled: December 30, 2019Publication date: April 16, 2020Inventors: Nan-Horng LIN, Chiu-Chen HUANG, Chien-Yu CHEN, Kuo-Ching CHU, Chi-Huey WONG, Han-Chung WU
-
Patent number: 10538592Abstract: The present disclosure relates to anti-SSEA4 antibodies and bindings fragments thereof comprising specific complementarity determining regions capable of high affinity binding to SSEA4 molecules and SSEA4-associated expressing tumor cells, such as breast cancer, pancreatic cancer, and renal cancer cells. The anti-SSEA4 antibodies and binding fragments induce ADCC or CDC effects in the targeted tumor cells and inhibit and/or reduce the cancer/tumor proliferation. The present disclosure also provides anti-SSEA4 antibodies and binding fragments thereof as a pharmaceutical composition for treating cancer. In addition, the anti-SSEA4 antibodies and binding fragments are useful in the diagnosis of cancers.Type: GrantFiled: August 22, 2017Date of Patent: January 21, 2020Assignee: CHO PHARMA, INC.Inventors: Nan-Horng Lin, Chiu-Chen Huang, Chien-Yu Chen, Kuo-Ching Chu, Chi-Huey Wong, Han-Chung Wu
-
Publication number: 20190328895Abstract: An antibody-drug conjugate (ADC) has a structure represented by Formula (I): a pharmaceutically acceptable salt thereof wherein Ab is an antibody without glycans (i.e., the protein portion an antibody); G1 and G2 are glycan moieties, which may be the same or different; Cn1 and Cn2 are conjugation moieties, which may be the same or different; L1 and L2 are linker moieties, which may be the same or different; D1 and D2; are drug units which may be the same or different; and x and y are independently an integer from 0 to 8, provided that x+y?0.Type: ApplicationFiled: November 14, 2017Publication date: October 31, 2019Applicants: CHO PHARMA INC.Inventors: Nan-Horng LIN, Charng-Sheng TSAI, Ting-Chun HUNG, Hong-Yang CHUANG
-
Patent number: 10407673Abstract: A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO:1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.Type: GrantFiled: June 18, 2018Date of Patent: September 10, 2019Assignees: CHO Pharma Inc., Academia SinicaInventors: Nan-Horng Lin, Lin-Ya Huang, Sachin S Shivatare, Li-Tzu Chen, Chi-Huey Wong, Chung-Yi Wu, Ting Cheng
-
Publication number: 20180298361Abstract: A mutant of Endos2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO:1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.Type: ApplicationFiled: June 18, 2018Publication date: October 18, 2018Applicants: Academia SinicaInventors: Nan-Horng Lin, Lin-Ya Huang, Sachin S. Shivatare, Li-Tzu Chen, Chi-Huey Wong, Chung-Yi Wu, Ting Cheng
-
Publication number: 20180291109Abstract: The present disclosure relates to anti-SSEA4 antibodies and bindings fragments thereof comprising specific complementarity determining regions capable of high affinity binding to SSEA4 molecules and SSEA4-associated expressing tumor cells, such as breast cancer, pancreatic cancer, and renal cancer cells. The anti-SSEA4 antibodies and binding fragments induce ADCC or CDC effects in the targeted tumor cells and inhibit and/or reduce the cancer/tumor proliferation. The present disclosure also provides anti-SSEA4 antibodies and binding fragments thereof as a pharmaceutical composition for treating cancer. In addition, the anti-SSEA4 antibodies and binding fragments are useful in the diagnosis of cancers.Type: ApplicationFiled: August 22, 2017Publication date: October 11, 2018Inventors: Nan-Horng LIN, Chiu-Chen HUANG, Chien-Yu CHEN, Kuo-Ching CHU, Chi-Huey WONG, Han-Chung WU
-
Publication number: 20180208561Abstract: A compound for treating a protein kinase-related disease or disorder having a structure of formula (I) wherein L is NR8 or O; R1, R2, R3, R4, R5, R6 and R7 are defined herein. Compounds of formula (I) are useful for inhibition of protein kinases.Type: ApplicationFiled: June 15, 2015Publication date: July 26, 2018Applicants: Development Center for Biotechnology, DCB-USA LLCInventors: Nan-Horng Lin, Chu-Bin Liao, Shao-Zheng Peng, Shih-Chieh Yen, Mann-Yan Kuo
-
Patent number: 10000747Abstract: A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO: 1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.Type: GrantFiled: August 23, 2017Date of Patent: June 19, 2018Assignees: Academia Sinica, CHO Pharma Inc.Inventors: Nan-Horng Lin, Lin-Ya Huang, Sachin S Shivatare, Li-Tzu Chen, Chi-Huey Wong, Chung-Yi Wu, Ting Cheng
-
Publication number: 20180133340Abstract: An antibody-drug conjugate (ADC) has a structure represented by Formula (I): [D2-L2-Cn2?yG2-Ab-Sg1?G1-L1-D1]x?? Formula (I) or a pharmaceutically acceptable salt thereof, wherein Ab is an antibody without glycans (i.e., the protein portion of an antibody); G1 and G2 are glycan moieties, which may be the same or different; Cn1 and Cn2 are conjugation moieties, which may be the same or different; L1 and L2 are linker moieties, which may be the same or different; D1 and D2 are drug units which may be the same or different; and x and y are independently an integer from 0 to 8, provided that x+y?0.Type: ApplicationFiled: November 14, 2017Publication date: May 17, 2018Applicant: CHO Pharma Inc.Inventors: Nan-Horng Lin, Charng-Sheng Tsai, Ting-Chun Hung, Hong-Yang Chuang
-
Publication number: 20180057804Abstract: A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO: 1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.Type: ApplicationFiled: August 23, 2017Publication date: March 1, 2018Applicants: CHO Pharma Inc., Academia SinicaInventors: Nan-Horng Lin, Lin-Ya Huang, Sachin S Shivatare, Li-Tzu Chen, Chi-Huey Wong, Chung-Yi Wu, Ting Cheng
-
Patent number: 9340558Abstract: A compound or its pharmaceutically acceptable salt, optionally including both individual enantiomeric forms, a racemate, diastereomers and mixtures thereof, composition and method are disclosed that can provide analgesia and reduce inflammation. A contemplated compound has a structure that corresponds to Formula A, wherein the R group substituents, d, e, f, k, n, m, D, E, F, K, G, P, Q, W, and Z are defined within.Type: GrantFiled: December 20, 2013Date of Patent: May 17, 2016Assignee: Pain Therapeutics Inc.Inventors: Lindsay Burns Barbier, Hoau-Yan Wang, Nan-Horng Lin, Andrei Blasko
-
Patent number: 9321762Abstract: A compound for treating a protein kinase-related disease or disorder having a structure of formula (I) wherein G is a heteroaryl, heterocyclic or alkyne; X is N or CH; L1 is —N(R7)—, —O—, —C(S)—, —C(O)—, or —S—; L2 is —N(R8)— or —O—; R1 and R2 are independently hydrogen, halogen, hydroxyl, amino, cyano, nitro, carboxy, C1-C4 alkoxy, C1-C4 alkoxy C1-C4 alkoxy, N,N—(C1-C4 dialkyl)amino C1-C4 alkoxy, N—(C1-C4 alkyl)amino C1-C4 alkoxy, C1-C4 alkanoyl, C1-C4 alkanoyloxy, N—(C1-C4 alkyl)amino, N,N—(C1-C4 dialkyl)amino, C1-C4 alkanoyl amino, or heterocyclyl, wherein C1-C4 alkyl is optionally substituted with one or more substituents selected from fluorine and chlorine; R3, R4 and R5 are independently hydrogen, fluorine or chlorine; R6 is C1-C4 alkyl or aryl, which is optionally substituted with one or more substituents selected from halogen, hydroxyl, amino, cyano, nitro; or R6 and R8 form a 5-6 membered cyclyl or heterocyclyl.Type: GrantFiled: December 11, 2013Date of Patent: April 26, 2016Assignee: Development Center for BiotechnologyInventors: Mann-Yan Kuo, Chu-Bin Liao, Shao-Zheng Peng, Shih-Chieh Yen, Nan-Horng Lin
-
Publication number: 20150158854Abstract: A compound for treating a protein kinase-related disease or disorder having a structure of formula (I) wherein G is a heteroaryl, heterocyclic or alkyne; X is N or CH; L1 is —N(R7)—, —O—, —C(S)—, —C(O)—, or —S—; L2 is —N(R8)— or —O—; R1 and R2 are independently hydrogen, halogen, hydroxyl, amino, cyano, nitro, carboxy, C1-C4 alkoxy, C1-C4 alkoxy C1-C4 alkoxy, N,N—(C1-C4 dialkyl)amino C1-C4 alkoxy, N—(C1-C4 alkyl)amino C1-C4 alkoxy, C1-C4 alkanoyl, C1-C4 alkanoyloxy, N—(C1-C4 alkyl)amino, N,N—(C1-C4 dialkyl)amino, C1-C4 alkanoyl amino, or heterocyclyl, wherein C1-C4 alkyl is optionally substituted with one or more substituents selected from fluorine and chlorine; R3, R4 and R5 are independently hydrogen, fluorine or chlorine; R6 is C1-C4 alkyl or aryl, which is optionally substituted with one or more substituents selected from halogen, hydroxyl, amino, cyano, nitro; or R6 and R8 form a 5-6 membered cyclyl or heterocyclyl.Type: ApplicationFiled: December 11, 2013Publication date: June 11, 2015Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGYInventors: Mann-Yan Kuo, Chu-Bin Liao, Shao-Zheng Peng, Shih-Chieh Yen, Nan-Horng Lin
-
Publication number: 20140113895Abstract: A compound or its pharmaceutically acceptable salt, optionally including both individual enantiomeric forms, a racemate, diastereomers and mixtures thereof, composition and method are disclosed that can provide analgesia and reduce inflammation. A contemplated compound has a structure that corresponds to Formula A, wherein the R group substituents, d, e, f, k, n, m, D, E, F, K, G, P, Q, W, and Z are defined within.Type: ApplicationFiled: December 20, 2013Publication date: April 24, 2014Inventors: Lindsay Burns Barbier, Hoau-Yan Wang, Nan-Horng Lin, Andrei Blasko